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Abstract: Hereditary diseases affecting 
the skeleton are heterogeneous in etiol-
ogy and severity. Though many of these 
conditions are individually rare, the 
total number of people affected is great. 
These disorders often include dental-
oral-craniofacial (DOC) manifesta-
tions, but the combination of the rar-
ity and lack of in-depth reporting often 
limit our understanding and ability 
to diagnose and treat affected individ-
uals. In this review, we focus on den-
tal, oral, and craniofacial manifesta-
tions of rare bone diseases. Discussed 
are defects in 4 key physiologic pro-
cesses in bone/tooth formation that 
serve as models for the understand-
ing of other diseases in the skeleton 
and DOC complex: progenitor cell dif-
ferentiation (fibrous dysplasia), extra-
cellular matrix production (osteo-
genesis imperfecta), mineralization 
(familial tumoral calcinosis/hyperos-
tosis hyperphosphatemia syndrome, 
hypophosphatemic rickets, and hypo-
phosphatasia), and bone resorption 
(Gorham-Stout disease). For each con-
dition, we highlight causative muta-
tions (when known), etiopathology in 
the skeleton and DOC complex, and 
treatments. By understanding how 
these 4 foci are subverted to cause dis-
ease, we aim to improve the identifica-
tion of genetic, molecular, and/or bio-
logic causes, diagnoses, and treatment 
of these and other rare bone conditions 
that may share underlying mechanisms 
of disease.
Key Words: fibrous dysplasia 
of bone, osteogenesis imperfecta, 
familial hypophosphatemic rickets, 
hypophosphatasia, hyperphosphatemic 
familial tumoral calcinosis, Gorham-Stout 
disease.
Introduction
Hereditary diseases affecting the 
skeleton, which we define to include 
the craniofacial and dental structure, 
are heterogeneous in etiology, onset, 
and severity. Although many of these 
conditions are individually rare (affecting 
less than 1 in 200,000), the total number 
of people affected is great (see the 
National Organization for Rare Disorders 
at www.rarediseases.org and the Rare 
Bone Disease Patient Network at 
http://www.usbji.org/projects/RBDPN_
op.cfm). Rare disorders are difficult to 
diagnose and are easily misdiagnosed; 
those of the skeleton are no exception. 
While progress has been made in 
our understanding of the underlying 
causes, pathologies, and mechanisms 
of bone diseases, those of the dental-
oral-craniofacial (DOC) complex are 
frequently overlooked or superficially 
reported. This has implications in terms 
of understanding, diagnosing, and 
treating affected individuals, in turn 
affecting health and quality of life.
Proper formation of the skeleton 
and dentition requires integration of 
numerous processes beginning in early 
embryonic development. These include 
patterning of the head, limbs, and 
skeletal/dental elements, cell migration 
and proliferation, differentiation to 
specialized cells, matrix secretion, 
biomineralization of bones and teeth, 
and remodeling of bone. For purposes 
of this review, we discuss 4 processes 
directly affecting the formation and 
function of craniofacial bones and teeth 
(Fig. 1) that can serve as models for an 
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understanding of basic pathophysiologic 
processes in the broader sense: 
progenitor cell differentiation, 
extracellular matrix production, 
mineralization, and resorption, a key step 
in remodeling of bone, but not teeth. For 
each of these processes, we highlight a 
disease or small number of diseases that 
occur(s) when that stage goes awry. By 
discussing mechanisms of how bone and 
tooth functions are negatively affected in 
these specific cases, we aim to identify 
patterns that can ultimately be applied 
to improve the identification of genetic, 
molecular, and/or biologic causes of 
additional diseases by their shared 
skeletal and dental etiopathologies. 
Appendix Table 1 summarizes additional 




Fibrous dysplasia of bone (FD; MIM 
174800) is caused by somatic activating 
mutations in the GNAS gene encoding the 
G-protein-coupled receptor-associated 




Mutations result in ligand-independent 
activation of the cAMP signaling pathway 
(Weinstein et al., 1991). In skeletal tissues, 
overproduction of cAMP impairs the 
ability of bone-forming mesenchyme 
to transition from stem-like immature 
cells to mature osteogenic cells. There 
is increased secretion of interleukin-6 
and expression of receptor activator for 
NFκB ligand (RANKL), both of which 
contain cAMP response elements in their 
promoters (Riminucci et al., 2003). The 
outcome is abnormal bone formation 
and remodeling characterized by fibrous 
tissue proliferation and expansion of the 
marrow or diploë by fibrous tissue that 
contains immature, structurally abnormal 
woven bone (Riminucci et al., 1997). 
The phenotype is broad, ranging from 
a single skeletal site (monostotic) to 
massive disease affecting multiple bones 
(polyostotic) (Fig. 2A). The phenotype is 
determined by when, and in which clonal 
cell in the inner cell mass, the sporadic 
mutation arises during development. The 
degree of clinical sequelae likewise varies, 
from asymptomatic to disfigurement 
with loss of function, including blindness 
Figure 1.
Diseases affecting specific stages of bone formation and remodeling. This model outlines key stages of bone development (differentiation of 
stem/progenitor cells, matrix production, mineralization, and resorption) affected by the genetic disorders highlighted in this review. For each 
developmental process (indicated by text boxes), associated diseases caused by defects in that process are identified. Tooth development 
depends on parallel processes outlined for bone formation, though notably does not undergo physiological resorption as part of a remodeling 
process.
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and deafness. When extra-skeletal sites 
are involved, such as skin (café-au-
lait macules) (Fig. 2B) and/or gonads 
(precocious puberty) (Fig. 2C), the 
disease is known as McCune-Albright 
syndrome (MAS). Hyperthyroidism, 
hypophosphatemia, and growth hormone 
excess can also occur in FD/MAS 
(Figs. 2D, 2E). Craniofacial bones are 
the most commonly involved skeletal 
sites in FD, especially the skull base, 
maxilla, and midface (Lee et al., 2002; 
Kelly et al., 2008) (Figs. 2A, 2F, 2G). 
There can be extensive expansion of 
the skull, maxilla, and mandible, tooth 
displacement, severe malocclusion, and 
facial disfigurement (Akintoye et al., 2003, 
2013) (Figs. 2G-2I). When associated 
with pituitary hypersecretion of growth 
hormone, overgrowth of craniofacial 
FD is associated with greater morbidity. 
Panoramic radiographs of jaw FD display 
ground glass trabeculation that may 
progress to mixed radiolucent/radiopaque 
lesions (Figs. 2J, 2K). Dental disorders 
associated with FD include enamel 
hypoplasia and hypomineralization, 
dentin dysplasia, odontoma, taurodontic 
pulp, and high caries index (Figs. 2I, 2L, 
2M). It is unclear whether FD-related 
cAMP excess affects tooth development, 
but taurodontism (Fig. 2K) seen in FD 
may be the combined effect of FD and 
endocrine dysfunction.
Diagnosis of FD and/or MAS involves 
careful clinical, radiographic, and 
occasionally histopathologic evaluation. 
Technetium-99 scintigraphy is useful for 
determining sites of skeletal involvement 
and disease burden. When this is 
combined with computed tomography 
(CT), the overall extent of the craniofacial 
disease can usually be determined in 
individuals by age 5 yr (Hart et al., 2007). 
Evaluation should include screening for 
hyperthyroidism, hypophosphatemia, and 
growth hormone excess. Histopathology 
of FD shows immature, irregular, woven 
bone, often with ectopic Sharpey’s fibers, 
abundant osteoid, in a fibrous stroma of 
variable cellularity, and often with active, 
osteoclast-mediated bone resorption  
(Fig. 2N).
The mainstay of FD treatment 
is surgery (Stanton et al., 2012). 
Intramedullary fixation devices are 
preferred for orthopedic procedures. 
However, craniofacial surgery should 
be undertaken with caution because of 
potential for the rapid regrowth of FD 
lesions. Optic nerve decompression is 
contraindicated in cases where nerves are 
constricted but vision is unaffected (Lee 
et al., 2002). Bisphosphonates are helpful 
to treat bone pain; however, no clear 
radiographic, functional, or histologic 
benefits have been demonstrated. There 
is evidence suggesting that, with age, 
mutant progenitor cells fail to self-renew, 
while surviving normal cells are able to 
form normal bone, thereby limiting the 




Osteogenesis imperfecta (OI) is a group 
of hereditary disorders characterized by 
variable bone fragility. Clinical diversity 
led to classification of OI into 4 subtypes 
based on clinical phenotype and mode of 
inheritance (Sillence et al., 1979). There 
are currently 15 OI subtypes caused by 
mutations involving 11 genes (Appendix 
Table 2). More than 90% of individuals 
with OI have heterozygous mutations 
in 1 of the 2 genes encoding type I 
collagen (CO1A1 and COL1A2), the most 
abundant matrix protein in bone, dentin, 
ligaments, sclera, and skin. OI types 
V-XV are caused by mutations in 1 of at 
least 9 different genes (Byers and Pyott, 
2012). These OI types are rare (about 
10% of total OI cases) compared with 
those caused by mutations in CO1A1 and 
COL1A2. There are hundreds of allelic 
mutations in these genes, and genotype-
phenotype relationships remain unclear 
in many instances, although mutations 
affecting different collagen-coding genes 
and types of mutations (e.g., splice 
mutations vs. glycine substitutions) are 
associated with differing degrees of 
clinical severity (Marini et al., 2007). 
Other causative genes for OI affect 
crosslinking and stabilization of the 
collagen fibril (e.g. PLOD2, FKBP10) 
or mineralization of fibrils (e.g., BMP1, 
which cleaves the C-terminus of  
collagen propeptide) (Byers and  
Pyott, 2012; Martinez-Glez et al.,  
2012).
Craniofacial and dental features for 
OI types III and IV are summarized 
in Fig. 3. Affected individuals suffer 
from decreased bone mineral density, 
increased fracture risk, deformations, 
short stature, kyphoscoliosis, craniofacial 
deformities, and a tooth phenotype 
resembling dentinogenesis imperfecta 
(DI). Wormian bones (intrasutural 
bones with unusually situated centers 
of ossification) are associated with OI 
and have been correlated with disease 
severity (Semler et al., 2010). Additional 
clinical manifestations include blue 
sclera, easy bruising, hearing loss, joint 
hypermobility, and hernias (van Dijk 
et al., 2011). DI-affected teeth tend to 
be smaller than normal, and feature 
constriction at the cementum-enamel 
junction, diminished roots, blue-gray 
to yellow-brown discoloration, and 
pulp chambers that are progressively 
diminished and appear obliterated on 
radiographs (Majorana et al., 2010). It 
is unclear why some OI mutations are 
associated with a DI phenotype, while 
others are not.
Clinical manifestations of OI are 
managed by a combination of intra-
osseous rods to reduce long bone 
fractures (Mulpuri and Joseph, 2000) and 
bisphosphonate infusions to improve 
bone density and manage bone pain 
(Ruck et al., 2011; Nicolaou et al., 2012). 
Oral bisphosphonates have been used 
with some success in milder OI cases. 
Despite concerns about bisphosphonate-
induced osteonecrosis of the jaw, 
to date there are no reports of this 
condition in patients with OI treated with 
bisphosphonates (Milano et al., 2011; 
Christou et al., 2013).
Management of the dentition when  
DI is present depends on the severity, 
and whether enamel fracturing 
occurs and results in excessive tooth 
breakdown. Crowning of the teeth is 
the treatment of choice in these cases, 
since intra-coronal restorations are not 
retained in DI teeth that are affected  
by enamel loss and excessive dentin 
loss.
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Figure 2.
Fibrous dysplasia (FD). (A) Technetium-99 bone scintigraphy of a female patient with FD/McCune-Albright syndrome (MAS) shows patchy 
areas of increased radiotracer uptake by FD in the craniofacial bones (black arrowheads), pelvis, and long bones (black arrows). (B) Café-
au-lait macules on the face of a boy with MAS macules display the typical jagged “coast of Maine” borders. (C) Testicular ultrasound of 
a patient with MAS displays heterogeneous mixed cystic and solid lesions characteristic of Leydig cell hyperplasia (white arrows). (D) 
Thyroid ultrasound of a patient with MAS and hyperthyroidism demonstrates characteristic heterogeneity with a cystic, “Swiss cheese”-like 
appearance (white arrow). (E) Magnetic resonance imaging of the brain of a patient with MAS-associated growth hormone excess displays a 
large, dumbbell-shaped growth-hormone- and prolactin-secreting pituitary macroadenoma (white arrows); the bright spot (black arrowhead) 
indicates the posterior pituitary. (F) Computed tomography (CT) of the head in this MAS patient shows right mandibular expansion by FD 
(white arrow). (G) Three-dimensional volume rendering of CT images of the same patient seen in panel F shows expansion of FD in the 
right mandible (white arrow), as well as smaller potential areas of FD in the right fronto-orbital region and midface (black arrowheads). (H) 
Severe expansion of the maxilla by FD (black stars) is associated with malocclusion and right-sided overbite (white arrow). (I) In another FD 
patient, malocclusion shows a right lingual crossbite (black arrows) and a left posterior open bite (white arrow), possibly from mandibular 
enlargement due to growth hormone excess. (J) Panoramic radiograph of mandibular FD shows radiolucent ground glass trabeculation 
(white arrow). (K) Another MAS patient with growth hormone excess displays generalized FD radiopacity, particularly in the maxilla, and 
taurodontic pulp chambers (black arrows). (L) Enamel hypomineralization (black arrowheads) and (M) dentin dysplasia (black arrowheads) 
are also dental features often seen in patients with FD/MAS. (N) Histologic features of FD shown in Goldner’s trichrome-stained section 
include immature irregular woven bone (WB) with Sharpey’s fibers (white arrows) in a fibrous tissue (FT) matrix of variable cellularity. Note 
the unmineralized osteoid (white star) indicating osteomalacia, and an osteoclast resorbing bone in Howship’s lacuna (black arrow). Images 
in C, D, F, E, and J reproduced with permission from Akintoye et al., 2013. Image in K reproduced with permission from Akintoye et al., 2003.
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Figure 3.
Osteogenesis imperfecta (OI). Clinical and radiographic findings in individuals with OI types III (A-C) and IV (D-F). (A) Facial appearance of 
child with OI type III shows a triangular face with prominent forehead and blue sclera. (B) Dentition of this child shows blue-gray discoloration 
characteristic of dentinogenesis imperfecta (DI). Discoloration is less pronounced in the maxillary permanent incisors than in the primary 
teeth. (C) A panoramic radiograph of the dentition of this child with OI type III shows cervical constriction and large pulp chambers in the 
six-year molars (white arrows), and diminished pulp space in the primary dentition (black stars) that has been restored with stainless steel 
crowns. (D) A cephalometric radiograph of an adult individual with OI type IV shows midface deficiency and a steep mandibular plane angle. 
(E) A panoramic radiograph of the dentition of the same individual displays obliteration of the pulp space and poor contrast of the roots to 
the bone due to the hypomineralized dentin (for example, mandibular teeth indicated by black arrows). This individual has required multiple 
root canals as a result of pulpal necrosis associated with DI. (F) A panoramic radiograph of an individual with OI type IV showing delayed 
dentin formation and large pulp chambers in the early-developing permanent dentition (see white arrows for examples), while the primary 
dentition is undergoing pulpal obliteration due to increased dentin formation (see white stars for examples).
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syndrome (FTC/HHS; MIM 211900) is 
an autosomal-recessive disorder arising 
from functional deficiency of intact 
fibroblast growth factor 23 (iFGF23), 
a phosphaturic hormone produced 
primarily by osteocytes and osteoblasts. 
Prior to secretion into the circulation, 
iFGF23 undergoes O-linked glycosylation 
by the galactosyl transferase, 
ppGalNacT3, encoded by UDP-N-acetyl-
alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 3 
(GALNT3). O-linked glycosylation 
protects iFGF23 from cleavage into 
inactive fragments by furin-like pro-
protein convertases (Kato et al., 2006). 
iFGF23 signaling requires Klotho, a 
co-receptor that converts a generic 
fibroblast growth factor (FGF) receptor 
into a specific FGF23 receptor (Urakawa 
et al., 2006). The underlying genetic 
causes of decreased iFGF23 action 
include loss-of-function mutations in 
FGF23 (Benet-Pages et al., 2005), GALNT3 
(Topaz et al., 2004), or KL (Ichikawa et 
al., 2007), which encodes Klotho (Farrow 
et al., 2011).
Decreased iFGF23 leads to stimulation 
of sodium phosphate co-transporters 
(NaP
i
-2a and-2c) and 25-OH-vitamin 
D
3
-1-α–hydroxylase in the proximal renal 
tubule. Hyperphosphatemia ensues from 
increased renal tubular reabsorption and 
increased gastrointestinal absorption 
of phosphate (P
i
). In addition, 






may enhance gastrointestinal absorption 
of P
i
 and calcium (Ca2+) (Farrow et al., 
2011). The increased Ca2+ x P
i
 product 
contributes to ectopic calcification 
(Yamaguchi et al., 1995).
Clinical manifestations include 
periarticular, subcutaneous, and soft-
tissue calcifications that tend to occur 
in areas of repeat trauma (Figs. 4A-4D). 
Calcifications may be associated with 
inflammation – ulceration of the 
overlying skin with milky drainage 
in severe cases. In addition to visible 
and palpable ectopic calcifications, 
radiographs often reveal cortical  
hyperostosis (Fig. 4E), which may  
cause diaphyseal pain of the long bones. 
Age-inappropriate calcification of the 
thyroid cartilage (Fig. 4F) has been 
described in one patient (Dumitrescu  
et al., 2009).
Dental findings include short bulbous 
teeth, shortened roots, root dilacerations, 
thistle-shaped dental pulps, pulp 
chamber and root canal obliteration, 
and pulp stones (Figs. 4G, 4H) (Burkes 
et al., 1991; Dumitrescu et al., 2009). 
Radiographs of younger individuals 
suggest that abnormal calcification of 
the pulp occurs prior to root formation. 
Histologically, the root phenotype 
resembles dentin dysplasia II (MIM 
125420), but the timing of calcification 
differs (Burkes et al., 1991). Alterations in 
gingiva and “velvety-red” lesions on the 
palate, mucosa, and tongue were noted 
in one family (Gal et al., 1994). However, 
other reports found no soft-tissue 
changes in the oral mucosa of patients 
with FTC/HHS. Large bilateral mandibular 
tori and bony sclerosis of the mandible, 
maxilla, and skull were reported in one 
patient (Krstevska et al., 2012).
Treatments for FTC/HHS have not been 
well-studied, and there is no standard 
regimen. Most reported therapies focus 




 diet is 
generally encouraged, although difficult 
for many to achieve. P
i
 binders such 
as sevelamer and aluminum hydroxide 
may decrease P
i
 absorption in the 
gastrointestinal tract. Medications that 
promote renal excretion of P
i
, such 
as acetazolamide and probenecid, 
are also used (Yamaguchi et al., 
1995; Lammoglia and Mericq, 2009). 
Clinical responses vary, ranging from 
complete resolution of calcific tumors 
to development of additional ectopic 
calcifications. When inflammation is 
present, anti-inflammatory medications 
may be beneficial. Surgical debulking 
is sometimes necessary in patients with 
functional impairment or severe pain, but 
is not routinely done, since tumors often 
recur.
Hypophosphatemic Rickets
Rickets arises from defects in factors 
that regulate mineral ion homeostasis, 
including 1,25(OH)
2




in biomineralization by stimulating 
gastrointestinal absorption of Ca2+ and 
P
i
, and initiating cell signaling via the 
intracellular vitamin D receptor (VDR). 
While the causes of rickets can be 
classified as primarily calciopenic or 
phosphopenic, evidence suggests that 
growth plate defects are primarily due to 
hypophosphatemia. In calciopenic forms 
of rickets, both nutritional vitamin D 
deficiency and rare inherited conditions 
affecting vitamin D action [loss-of-
function of 1α(OH)ase from CYP27B1 
mutations in vitamin D-dependent rickets 
type 1, VDDR-I (MIM 264700), or loss 
of VDR function in VDDR-IIa (MIM 
277440)], lead to hypocalcemia and 
hypophosphatemia (the latter induced by 
secondary hyperparathyroidism).
Many hereditary forms of primary 
hypophosphatemic rickets arise 
from mutations affecting renal P
i
 
handling. The most common type of 
hypophosphatemic rickets is X-linked 
hypophosphatemia (XLH; MIM 307800), 
caused by inactivating mutations in PHEX 
(phosphate-regulating endopeptidase 
homolog, X-linked). More recently, 
mutations in the gene for dentin matrix 
protein 1 (DMP1) were linked with type 
1 autosomal-recessive hypophosphatemic 
rickets (ARHR1; MIM 241520). This was 
a surprise, since DMP1 was known as 
an extracellular matrix protein in dentin 
and bone. ARHR also results from 
mutations in the ENPP1 gene encoding 
ectonucleotide pyrophosphatase 
phosphodiesterase 1 (ARHR2; MIM 
613312), a membrane-bound ectoenzyme. 
Loss-of-function of ENPP1 was previously 
associated with generalized arterial 
calcification of infancy. It remains 
unclear why the disparate mutations 
responsible for XLH, ARHR1, and 
ARHR2 all result in elevated iFGF23. 
Increased iFGF23 is thought to be the 
driving force for hypophosphatemia and 
reduced 1,25(OH)
2
D, which contribute 
to disturbances in skeletal and dental 
mineralization. Autosomal-dominant 
13S
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Figure 4.
Familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome (FTC/HHS). Clinical, radiographic, and histologic findings of patients 
with FTC/HHS. (A) Erythematous, inflamed subcutaneous calcifications of the neck and (B) periarticular ectopic calcification of the elbow 
in a 9-year-old girl. (C) Radiograph with extensive periarticular ectopic calcification of the right hip (white arrows). (D) Histology of ectopic 
calcification with amorphous calcium deposits (arrowheads) surrounded by a thick infiltration of mono- and poly-nucleated macrophages 
(“foreign body macrophages”), associated with a chronic inflammatory reaction. (E) Radiograph showing periarticular ectopic calcification 
of the right elbow (white arrow) and diaphyseal hyperostosis of the radius and humerus (white arrowheads). (F) Lateral neck radiograph 
showing age-inappropriate calcification of the thyroid cartilage in a 36-year-old woman (white arrow). (G) Panoramic dental radiograph 
of a 9-year-old girl with blunted, bulbous roots and obliteration of the pulp chamber in the maxillary and mandibular permanent central 
and lateral incisors. The erupting permanent premolars exhibit calcification at the root apices. Sclerotic bony changes are also present 
around the erupting teeth (white arrows). (H) Periapical radiograph of mandibular right sextant showing thistle-shaped roots (white arrows), 
midroot bulges (white arrowheads), and mineralized molar pulps and root canals (white star) in a 36-year-old woman. Images in F and H 
reproduced with permission from Dumitrescu et al., 2009.
14S
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hypophosphatemic rickets (ADHR; MIM 
193100), with a similar clinical and 
biochemical phenotype, is caused by 
missense mutations in the FGF23 gene, 
resulting in a proteolytically resistant 
FGF23, thus increasing circulating iFGF23.
The skeletal manifestations of these 
disorders can be separated into 
rickets, growth plate abnormalities that 
occur in children, and osteomalacia, 
defective mineralization that occurs 
throughout the skeleton in children and 
adults. Rickets manifests clinically as 
widening of the distal long bones, often 
evident at the wrists, knees, ankles, 
and ribs, radiographically as widened 
growth plates with frayed and cupped 
metaphyses (Fig. 5A). Osteomalacia, 
causing bowing deformities, is a tissue 
diagnosis where staining demonstrates 
unmineralized (osteoid) matrix (as in 
Fig. 2N or 5I). Craniofacial manifestations 
include enlarged cranial sutures, delayed 
fontanelle closure, craniotabes (skull 
bone thinning and softening), and 
malformations of the cranium, including 
parietal and occipital flattening and 
frontal bossing. Craniosynostosis has 
been documented in VDDR and XLH, 
often in the second or third year of life, 
leading to scaphocephaly (anterior-
posterior elongation of the cranium), 
elevated intracranial pressure, and 
papilledema (optic disc swelling) 
(Glass et al., 2011) (Figs. 5B, 5C). 
Cephalometric analysis in patients 
with osteomalacia shows alterations 
in bones of both endochondral and 
intramembranous origin (Gjørup et al., 
2011). While the mineralization disorders 
and malformations are explained by 
hyperosteoidosis, the etiology for 
craniosynostosis remains unclear. One 
hypothesis involves FGF23-FGFR2 
signaling in the areas of the sutures.
Delayed tooth eruption is frequently 
cited in cases of XLH (Foster et al., 
2014). There have been several case 
reports on dental manifestations of 
VDDR and XLH, and limited numbers 
of publications on ARHR and ADHR 
are consistent with these pathologies. 
The rachitic tooth features defects in all 
the dental hard tissues. These include 
hypoplastic enamel that is easily abraded 
and fractured and subject to caries, thin 
and poorly mineralized dentin, enlarged 
pulp chambers, predisposition to dental 
abscesses, short and malformed roots, 
periodontal disease, and sometimes 
malocclusion (Figs. 5D-5G). Animal 
studies show that enamel defects arise 
from a combination of altered vitamin D 
metabolism along with hypocalcemia  
and hypophosphatemia (Berdal  
et al., 2011). Dentin mineralization is 
consistently affected across all forms 
of hypophosphatemic rickets, with the 
histologic presence of interglobular 
dentin indicating inhibition of growth of 
mineralization foci, likely arising from 
a combination of hypophosphatemia, 
elevated levels of circulating mineral 
inhibitors, and reduced active 
1,25(OH)
2
D. The hypomineralized dentin 
is prone to fractures and predisposes 
teeth to infection and abscess. 
Periodontal problems likely arise from 
a combination of osteomalacia in the 
alveolar bone and root surface defects in 
the cementum (Foster et al., 2014).
Vitamin D disorders are treated 
with vitamin D analogues and Ca2+; 
VDDR-II is refractory to calcitriol due 
to impaired VDR function. Children 
with hypophosphatemic rickets are 
typically administered calcitriol and P
i
, 
which can improve skeletal (and dental) 
manifestations (Chaussain-Miller et al., 
2007). In cases of craniosynostosis, 
surgical interventions such as cranial 
vault expansion are necessary to allow 
for cranial growth and to alleviate 
intracranial pressure (Murthy, 2009).
Hypophosphatasia
Hypophosphatasia (HPP) is 
characterized by poor bone 
mineralization resulting from loss-of-
function mutations in ALPL, encoding 
tissue-nonspecific alkaline phosphatase 
(TNAP) (Whyte, 1994). More than 267 
HPP-associated mutations in ALPL have 
been identified, passed in dominant 
or recessive mode (http://www.sesep.
uvsq.fr/03_hypo_mutations.php). TNAP 
is an ectoenzyme that hydrolyzes (thus 
reducing) inorganic pyrophosphate (PP
i
), 
a potent mineralization inhibitor. In 
addition to expression by chondrocytes 
and osteoblasts, TNAP is found in the 
dentoalveolar complex, with wide 
expression in the periodontium, dentin-
pulp complex, and enamel organ (Foster 
et al., 2012).
Six clinical forms of HPP have been 
identified, varying in severity and age of 
onset (Reibel et al., 2009). Infantile and 
childhood HPP (MIM 241500, 241510) 
causes a widely hypomineralized 
skeleton (including rickets), short stature, 
and waddling gate. Adult HPP (MIM 
146300) presents during middle age and 
features osteomalacia, bone pain, and 
stress fractures (Figs. 5H, 5I) (Berkseth 
et al., 2013). An intriguing aspect of 
HPP is the tooth-specific clinical isotype, 
odontohypophosphatasia, in which 
serum ALP is decreased and urinary 
phosphoethanolamine increased, but 
skeletal development is not (evidently) 
impaired, and tooth loss is the primary 
clinical sign (Mornet, 2007).
Severe forms of HPP feature 
hypomineralized regions of calvarial 
bone that radiographically appear 
as widely open fontanelles, though 
functional craniosynostosis (closure) can 
occur, leading to increased intracranial 
pressure and a bulging anterior fontanel 
(Whyte, 1994; Collmann et al., 2009) 
(Figs. 5J, 5K). Wormian bones are 
sometimes present in infantile and 
childhood HPP.
Observations of premature tooth loss 
led to the finding that root acellular 
cementum is defective in HPP, resulting 
in compromised periodontal attachment 
(Figs. 5L-5O). Reduction in alveolar 
bone height reflects bone loss due to 
poor periodontal attachment. Defects 
in dentin and enamel mineralization 
have been reported, though not 
consistently. The dentin phenotype 
includes widened pulp chambers, “shell 
teeth” with thin root dentin, and short, 
abnormally shaped roots (Figs. 5L-5N), 
related to developmental defects in the 
initial mantle dentin layer (Foster et al., 
2012), likely parallel to effects causing 
osteomalacic bone and similar to effects 
in hypophosphatemic rickets, described 
above.
Results from translational studies  
and clinical trials with a recombinant 
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Figure 5.
X-linked hypophosphatemic rickets (XLH) and hypophosphatasia (HPP). Representative images of individuals with hypophosphatemic rickets (A-
G) and hypophosphatasia (H-O). (A) Skeletal pathology resulting from osteomalacia includes bowing of the femur (arrow) due to softening of the 
bone. (B) The computed tomography (CT) scan of a 3-year-old female with XLH shows scaphocephaly (elongation of the skull), suggestive of 
premature fusion of the sagittal suture. (C) Brain CT (left image) from the same patient shows enlargement of optic nerve sheaths (red arrows) due 
to papilledema (optic disc swelling), while orbital CT shows ventricular narrowing and decreased size of ventricles (white arrows) due to synostoses, 
contributing to elevated intracranial pressure. (D) Enamel discoloration indicating hypoplasia in a juvenile individual diagnosed with XLH, and (E) 
dental radiograph from the same individual features thin dentin and wide pulp chambers (white arrows). (F) Histologic staining reveals interglobular 
dentin hypomineralization, reflecting inhibition of mineralization foci to fuse into a unified mineralization front, a pattern replicated in (G) scanning 
electron microscopy from an adult individual with XLH. (H) Radiograph of pseudofracture of the proximal femur (white arrow) in adult diagnosed 
with HPP. (I) Goldner’s trichrome stain of iliac crest biopsy from adult diagnosed with HPP, exhibiting excess osteoid (red layer indicated by black 
arrow). (J) Magnetic resonance imaging (MRI) of the skull of a six-year-old individual diagnosed with childhood HPP exhibiting craniosynostosis 
and resulting bregmatic eminence (white arrow). (K) Radiograph of a four-year-old HPP individual with hypomineralization of cranial vault exhibiting 
severe “copper beaten” skull appearance, as well as deformations of cranial vault shape. Alterations in cranial shape in J and K are indicative of 
increased cranial pressure. (L) Clinical photograph of a fourteen-year-old individual with HPP who experienced spontaneous exfoliation of the lower 
mandibular incisor during toothbrushing. (M) Panoramic radiograph of the same individual revealing delayed eruption of several permanent teeth 
(e.g., lower premolars), enlarged pulp chambers, and thin dentin. (N) Periapical radiograph of the same patient at 20 yr old, showing loss of lower 
incisor, endodontic treatment, and splinting of remaining incisors, with generalized loss of alveolar bone. (O) Scanning electron microscopy of incisor 
root from HPP patient indicates lack of cementum and exposure of dentin (*), as well as extensive resorption over the root surface. Images in B and 
C adapted from Glass et al. (2011); reproduced under open access policy. Images in D-F are adapted from Pereira et al. (2004) and are reproduced 
with permission. Image in G was adapted from Foster et al. (2013) and is reproduced by permission. Images in H and I are adapted from Berkseth 
et al. (2013) and are reproduced with permission. Images in J and K are adapted from Collmann et al. (2009) and are reproduced with permission. 
Images in L, M, and O are adapted from Rodrigues et al. (2012) and are reproduced with permission. Image in N is adapted from Rodrigues et al. 
(2012), and is reproduced by permission.
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bone-targeting TNAP suggest that this is a 
potentially life-saving treatment for severe 
HPP, with potential to improve skeletal 
and dental function in less-impaired 
individuals with HPP (Millán et al., 2008; 
Whyte et al., 2012).
Bone Resorption
Gorham-Stout Disease
Gorham-Stout disease (GSD), also 
known as massive osteolysis, vanishing 
or disappearing bone disease, is an 
extremely rare disorder (MIM 123880). 
The first patient was described in 1938, 
and in 1955, Gorham and Stout described 
the disease as “angiomatosis,” or 
proliferation of small, thin-walled blood 
vessels (Gorham and Stout, 1955). With 
about 200 cases reported in the literature, 
much about GSD remains unknown.
Histopathologically, the disease is a 
benign vascular proliferation of endothelial 
channels within bone, leading to extreme 
thinning of bony trabeculae, osteoclast-
mediated resorption, and replacement 
of bone with fibrous tissue. Gorham and 
Stout postulated that hemangiomatosis 
led to hyperemia, causing excessive bone 
destruction. Hypotheses have included 
local hypoxia/acidosis and endothelial 
dysplasia (Heyden et al., 1977; Young  
et al., 1983), enhanced osteoclastic activity or 
increased sensitivity of osteoclast precursors 
to humoral factors (e.g., IL-1, IL-6, and  
TNF-α) (Devlin et al., 1996; Moller  
et al., 1999; Hirayama et al., 2001), or 
trauma (Al-Jamali et al., 2012). Another 
hypothesis proposes GSD as a form of 
lymphangiomatosis, a disease of soft tissue 
secondary to aberrant proliferation of 
lymphatic vasculature, placing these diseases 
on the same pathophysiologic spectrum.
GSD occurs sporadically, without 
apparent predilection for age, race, or 
gender. Most cases occur in individuals 
under the age of 40 yr, affecting 
mostly children and young adults. The 
disease can be progressive (Fig. 6) and 
lethal when associated with extensive 
involvement of the ribs, vertebrae, and 
pleural effusions. However, in some 
cases, it may be self-limiting. GSD can be 
monostotic or polyostotic; affected areas 
include the shoulder, pelvis, scapula, 
clavicle, ribs/sternum, femur, and skull. 
About 30% of reported patients with GSD 
have maxillofacial involvement, most 
frequently in the mandible (Kiran and 
Anupama, 2011). Pain is not a common 
finding; however, during the acute 
resorptive phase, pain, swelling, and 
progressive deformity may be present. 
In the dentoalveolar region, findings 
may include mobile teeth, malocclusion, 
mandibular deviation, bony deformity, 
and pathologic fractures (Fig. 6).
Radiographically, bone undergoes 
a series of changes in GSD. The first 
stage is marked by patchy bone with 
intramedullary and subcortical lucencies. 
In the second stage, new areas of lucency 
appear, with confluence of the lesions. 
The third stage involves adjacent soft 
tissues and cortical breakdown. The 
last stage results in complete resorption 
of bone and replacement with fibrous 
tissue. Magnetic resonance imaging 
(MRI) shows low signal intensity on 
T1-weighted imaging and high signal 
intensity on T2, with enhancement 
on contrast imaging (Ruggieri et al., 
2011). Technetium bone scan is not a 
reliable modality, since intensity is stage-
dependent. In the maxillofacial region, 
panoramic radiographs and CT scans 
are preferred for monitoring disease 
progression. While tooth resorption has 
not been reported, tooth loss may result 
from reduced alveolar bone.
Knowledge gaps in pathophysiology 
have prevented standardized 
treatment guidelines for GSD and 
lymphangiomatosis. Surgery is 
necessary for pathologic fractures and 
reconstruction after massive resorption. 
Prostheses may offer advantages over 
bone grafts because of the potential 
for recurrent osteolysis. Radiotherapy 
may limit disease spread by inhibiting 
the proliferation of disease-causing 
cells (Lowing et al., 2007). Medical 
therapies include bisphosphonates and 
interferon gamma; however, neither 
has demonstrated definitive benefit 
(Kuriyama et al., 2010). Additional studies 
have focused on the proliferation of 
endothelial cells, and the role of the 
mTOR pathway in lymphangiogenesis, 
leading to new potential therapeutic 
targets (Reinglas et al., 2011). Prognosis 
depends on the extent and location of 
affected areas. Mild disease may stabilize 
and ultimately reverse over time, while 
severe cases involving the craniofacial 
and/or thoracic areas may be fatal.
Conclusion
In this review, we outlined the effects 
of rare skeletal diseases on the DOC 
complex, focusing on 4 physiologic 
processes exemplified by specific genetic 
defects: FD as a defect in progenitor cell 
differentiation, OI caused by defective 
matrix production, FTC/HHS and 
HPP as mineralization disorders, and 
GSD as an example of excessive bone 
resorption (Fig. 1). From these examples, 
it is apparent that the formation and 
function of the skeleton and dentition are 
compromised when defects arise in any 
one of these processes. Other rare bone 
diseases with DOC effects are summarized 
in Appendix Table 1.
In addition to the conditions covered 
here, numerous undiagnosed skeletal 
diseases exist. Overlap between the 
underlying pathophysiology of these 
etiologically elusive conditions with 
that of known diseases may point to 
commonalities in their mechanisms. 
By understanding how defects in the 
development and maintenance of bones 
and teeth are subverted to cause disease, 
we aim to broaden the understanding, 
diagnosis, and treatment of rare skeletal 
diseases sharing underlying mechanisms. 
This is a paradigm currently used by 
the NIH Undiagnosed Disease Program 
(Office of Rare Disease Research; http://
rarediseases.info.nih.gov/) and a goal 
of skeletal and craniofacial researchers 
elsewhere. This approach has led to the 
diagnosis of newly recognized diseases 
such as arterial calcification due to 
deficiency of CD73 (ACDC; MIM 211800), 
and identification of causative mutations 
in rare diseases including Raine syndrome 
(MIM 259775) and Winchester syndrome 
(MIM 277950).
When new rare skeletal diseases are 
recognized, it is important for these 
patients to be referred to a craniofacial/
dental team for clinical evaluation, 
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Figure 6.
Gorham-Stout disease (GSD). Progressive destruction of the mandible in an individual with GSD, initially presenting at age 4 yr with mobility 
of left mandibular primary teeth, and premature exfoliation of the left mandibular primary first molar. (A) Panoramic radiograph, age 6 yr. 
Note normal complement of permanent teeth (left mandibular primary first molar #L missing) and abnormal left mandibular condyle. (B) 
Computed tomography (CT), age 6 yr. Destruction of normal cortical architecture of mandibular condyle, ramus, and body, bilaterally (white 
arrows). (C) Panoramic radiograph, age 7 yr (post-treatment with Interferon-α2b and zoledronic acid). Further bony changes with complete 
loss of left mandibular angle (white arrow). (D) CT, age 7 yr. Remodeling changes of the left mandibular condyle and ramus (white arrows). 
(E) Panoramic radiograph, age 10 yr. Loss of bony continuity in the left mandible (white arrow); teeth appear to be “floating.” Permanent 
tooth formation has progressed (left mandibular canine, white star). (F) CT, age 10 yr. Tooth buds appear to hold remaining bone together in 
left mandible. (G) CT, age 12 yr. Interval disease progression and bone loss of the bilateral mandible. Radiographs courtesy of Dr. Leonard B. 
Kaban, Massachusetts General Hospital, Department of Oral and Maxillofacial Surgery, Boston, MA, USA.
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the collection of clinical materials for 
translational studies, the monitoring of 
development over time, and treatment 
when possible. Only through this 
careful approach can we accomplish 3 
issues of paramount importance: (1) to 
provide answers and appropriate care to 
individuals suffering from conditions that 
have eluded diagnosis, (2) to advance 
medical knowledge about rare diseases 
of the skeleton and dentition, and (3) to 
develop and improve treatments for these 
diseases.
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